
Triple agonist acting on GLP-1, GIP, and Glucagon receptors — the most advanced molecule in its class, currently in Phase III clinical trials.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly on the backbone of human GIP, modified with non-natural amino acid substitutions and a 20-carbon fatty diacid attached to a lysine residue. That lipid chain binds plasma albumin and extends the half-life to roughly six days, which is why the entire clinical program was designed around once-weekly administration. Unlike first-generation GLP-1 agonists, it is a single molecule acting on three different receptors.
The mechanism under study is simultaneous agonism of the GLP-1, GIP and glucagon receptors. The first two reduce food intake and improve the glucose response; the glucagon component adds increased energy expenditure and hepatic lipid oxidation, an effect dual agonists lack. In preclinical models that third receptor was precisely what set the molecule apart, and the Phase 2 trials published in NEJM and The Lancet (2023) showed the same pattern in humans, including a marked drop in liver fat among participants with fatty liver.
The Phase 3 TRIUMPH program (obesity, type 2 diabetes, knee osteoarthritis, cardiovascular risk and a head-to-head against tirzepatide) began reporting in 2025–2026; the details are in the guides linked below. To date retatrutide has no regulatory approval in any country and remains an investigational molecule. The most frequent adverse effects in trials are gastrointestinal and escalation-dependent; increases in heart rate and transient skin sensations were also described. The material Renova distributes is strictly for research use (RUO), with independent purity analysis published at /en/coa/.
| Class | Triple GLP-1 / GIP / glucagon receptor agonist (lipidated peptide) |
| Development code | LY3437943 (Eli Lilly) |
| Structure | 39 amino acids on a GIP backbone, with Aib residues and a C20 fatty diacid linked to lysine |
| CAS | 2381089-83-2 |
| Reported half-life | ≈ 6 days (albumin binding) — basis of the weekly schedule used in trials |
| Regulatory status | Phase 3 (TRIUMPH program); not approved in any country |
| Sensitivity | Protect from light; avoid vigorous shaking of the solution (lipidated peptide, foams easily) |
Semaglutide activates one receptor (GLP-1), tirzepatide two (GIP and GLP-1) and retatrutide three: GIP, GLP-1 and glucagon. The glucagon receptor adds energy expenditure and hepatic fat oxidation, which is why the drop in liver fat in Phase 2 trials exceeded what dual agonists showed. It is also why its adverse-effect profile is not identical.
No. As of late 2026 it remains in Phase 3 (the TRIUMPH program) with no approval from the FDA, the EMA or the Dominican DIGEMAPS. Everything in circulation is research material. Renova distributes it only as an RUO reagent, not as a medicine.
TRIUMPH covers obesity (TRIUMPH-1), obesity with type 2 diabetes (TRIUMPH-2), cardiovascular risk (TRIUMPH-3), knee osteoarthritis (TRIUMPH-4) and a head-to-head with tirzepatide (TRIUMPH-5). Results reported between 2025 and 2026 are summarized in our retatrutide guides, including the TRIUMPH-2 readout presented at EASD 2026.
The ready presentation is already reconstituted and calibrated; the lyophilized powder requires bacteriostatic water and exact weighing. Both come from the same type of material and are verified with the same method (HPLC + mass spectrometry). Our cost-per-mg guide compares the two.
Related reading: Retatrutide: Triple GLP-1 / GIP / Glucagon Agonist · Retatrutide in Phase 3: What TRIUMPH-2 Showed at EASD 2026 · Retatrutide and knee pain: what TRIUMPH-4 and TRIUMPH-1 showed at ACR 2026 · Tirzepatide vs Retatrutide: Mechanism, Studies and Dose Differences · Black-Market Retatrutide: The Study That Measured the Gap With the Trials
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
How much does Retatrutide cost in the DR? The price of every presentation is shown above in US dollars (USD) next to its Dominican peso equivalent (RD$), and it is the same nationwide: in Santo Domingo our own team delivers at no charge (approx. 2–4 business hours); for the rest of the country, RD$400 courier is added (approx. 6–12 business hours). Buying 3 or more units of the same product unlocks volume pricing. To compare presentations, see the cost per mg in the DR.
Zones: Santo Domingo · Santiago · Punta Cana · La Romana
Delivery in Santo Domingo in about 2–4 business hours and nationwide in about 6–12 business hours by courier with tracking (RD$400). Reconstituted compounds travel cold-chain (2–8°C) in thermal packaging.
Yes — the Retatrutide certificate of analysis (Janoshik Analytical, HPLC + mass spectrometry) is published at renovapeptides.do/en/coa/#coa-retatrutide-60mg, verifiable by test number.
Orders are confirmed over WhatsApp. Payment: Payment Link (PayPal — card, Apple Pay or Venmo), bank transfer, or pay on delivery in Santo Domingo (cash or transfer on receipt).
There is no minimum order. Automatic cart discounts: same-product volume (3+ units 15%, 5+ 25%, 10+ 40%) and Mix & Match across different products (3+ items 10%, 5+ 15%, 7+ 20%; not applicable to Retatrutide or Tirzepatide). The better of the two applies per product; bacteriostatic water is excluded and promo codes can't be combined.
📖 Full guide: Retatrutide: Triple GLP-1 / GIP / Glucagon Agonist
Your cart is empty